Clene Inc. (CLNN) Stock Price & Analysis
Clene Inc. (CLNN) fell 2.26% to USD 3.54 as of September 9, 2026 at 14:42 UTC, according to Nexqual real-time market data.
CLNN last closed at USD 3.54; the session ranged USD 3.54–3.84 on volume of 51,876 shares. Market capitalization is —, with a 52-week range of USD 3.54–13.5 (NCM). Source: Nexqual, September 9, 2026 at 14:42 UTC.
Key Statistics (as of September 9, 2026 at 14:42 UTC)
| Price | USD 3.54 |
|---|---|
| Change | ▼ 2.26% (down) |
| Previous Close | USD 3.54 |
| Open | USD 3.54 |
| Day Range | USD 3.54 – 3.84 |
| 52-Week Range | USD 3.54 – 13.5 |
| Volume | 51,876 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (CLNN)
Nexqual's technical model rates CLNN "SELL" based on 3 bullish and 5 bearish signals across 128 daily candles, as of September 9, 2026 at 14:42 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.3 (oversold) |
| vs SMA50 | Below (USD 5.04) |
| MACD | -0.34 (negative) |
From Clene Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- These include:       Our CSN  Therapeutics Platform   By uniting concepts from electrochemistry, nanotechnology, plasma and quantum physics, materials science, and biochemistry, we have created and refined a proprietary electrocrystallization method that results in single component or multiple component nanocrystals of the transition elements that are clean-surfaced, highly faceted, and biologically catalytically active (see Figure 1 for example nanocrystals).
- The HEALEY ALS Platform Trial is the first platform trial for ALS and is intended to accelerate the development of ALS therapies by simultaneously testing multiple therapeutics under a master protocol, in order to reduce costs, decrease trial time, and increase patient participation.
- The new analysis incorporated up to 42 months (3.5 years) of survival follow-up and 76 weeks of long-term NfL biomarker results, including an NfL responder subset (the "CNM-Au8 NfL Responders") from the HEALEY ALS Platform Trial who had consistent and sustained NfL reductions, comprising nearly half of all CNM-Au8 patients.
- To our knowledge, we believe we are the only company currently developing catalytically-active nanocrystals to directly modulate biological systems as therapeutic drug candidates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DRMA | Dermata Therapeutics, Inc. | USD 1.23 | ▲ 1.65% |
| EVAX | Evaxion A/S | USD 3.28 | ▲ 5.13% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.48 | ▲ 5.04% |
| UNCY | Unicycive Therapeutics, Inc. | USD 5.08 | ▼ 1.55% |
| INAB | IN8bio, Inc. | USD 1.13 | ▼ 6.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 14:42 UTC. This page is informational and not investment advice.